BI Asset Management Fondsmaeglerselskab A S Buys 36,731 Shares of Medpace Holdings, Inc. $MEDP

BI Asset Management Fondsmaeglerselskab A S increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 247.1% in the 1st quarter, Holdings Channel reports. The fund owned 51,598 shares of the company’s stock after buying an additional 36,731 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Medpace were worth $24,777,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Optiver Holding B.V. purchased a new stake in Medpace during the third quarter valued at about $27,000. Geneos Wealth Management Inc. boosted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Medpace during the 4th quarter valued at about $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace during the 4th quarter valued at about $30,000. Finally, Quarry LP purchased a new position in shares of Medpace during the 3rd quarter valued at about $35,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MEDP shares. BMO Capital Markets cut their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Royal Bank Of Canada decreased their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Robert W. Baird cut their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, Barclays cut their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $467.08.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 20.50% of the company’s stock.

Medpace Price Performance

Shares of MEDP stock opened at $460.20 on Friday. The business has a 50-day moving average of $452.12 and a 200 day moving average of $499.49. Medpace Holdings, Inc. has a 1-year low of $301.90 and a 1-year high of $628.92. The stock has a market capitalization of $13.14 billion, a PE ratio of 28.93, a P/E/G ratio of 2.33 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the previous year, the firm earned $3.67 EPS. The business’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.